Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | TLR4 | O00206 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9946010 | 0.91 | ERN1 (0.35) | ERN1ALDH1A1CYP1A2CYP2C19MEN1 | |
| SCHEMBL9946012 | 0.84 | SRC (0.45) | ERN1ALDH1A1CYP1A2CYP2C19MEN1 | |
| SCHEMBL15106618 | 0.77 | SRC (0.44) | ERN1ALDH1A1CYP1A2CYP2C19TLR4 | |
| SCHEMBL14988453 | 0.77 | ALDH1A1 (0.49) | ALDH1A1MEN1KMT2AHPGDHTT | |
| SCHEMBL16687428 | 0.74 | ALDH1A3 (0.41) | ERN1KDM4ESRC | |
| SCHEMBL9097669 | 0.73 | FDPS (0.47) | ALDH1A1MEN1KMT2AHPGDHTT | |
| SCHEMBL23996066 | 0.72 | KDM4E (0.31) | KDM4E | |
| SCHEMBL1300716 | 0.72 | ERN1 (0.39) | ERN1ALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL565487 | 0.71 | ALDH1A1 (0.50) | ALDH1A1CYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL12538919 | 0.71 | SRC (0.47) | ERN1ALDH1A1CYP1A2CYP2C19KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220015367-A1 | SELF-ASSEMBLED ACTIVE AGENTS | METHODS PRODUCTS PBC | 2022-01-20 | — | — | US | claimed |
| US-20180303100-A1 | SELF-ASSEMBLED ACTIVE AGENTS | METHOD PRODUCTS, PBC | 2018-10-25 | — | — | US | claimed |
| WO-2018164994-A1 | SELF-ASSEMBLED ACTIVE AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2018-09-13 | — | — | WO | claimed |
| US-20240373854-A1 | SELF-ASSEMBLED ACTIVE AGENTS | METHODS PRODUCTS PBC | 2024-11-14 | — | — | US | disclosed |
| US-11723362-B2 | Broad-spectrum synergistic antimicrobial compositions | -The United States of America, as represented by The Secretary of Agriculture (US) | 2023-08-15 | — | — | US | disclosed |
| EP-4030915-A1 | BROAD-SPECTRUM SYNERGISTIC ANTIMICROBIAL COMPOSITIONS | The United States of America as represented by the Secretary of Agriculture (US) | 2022-07-27 | — | — | EP | disclosed |
| US-20220015367-A1 | SELF-ASSEMBLED ACTIVE AGENTS | METHODS PRODUCTS PBC | 2022-01-20 | — | — | US | disclosed |
| US-20220015367-A1 | SELF-ASSEMBLED ACTIVE AGENTS | METHODS PRODUCTS PBC | 2022-01-20 | — | — | US | disclosed |
| US-11166464-B2 | Self-assembled active agents | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2021-11-09 | — | — | US | disclosed |
| US-11166464-B2 | Self-assembled active agents | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210084896-A1 | BROAD-SPECTRUM SYNERGISTIC ANTIMICROBIAL COMPOSITIONS | METHOD PRODUCTS, PBC, | 2021-03-25 | — | — | US | disclosed |
| US-20180303100-A1 | SELF-ASSEMBLED ACTIVE AGENTS | METHOD PRODUCTS, PBC | 2018-10-25 | — | — | US | disclosed |
| WO-2018164994-A1 | SELF-ASSEMBLED ACTIVE AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2018-09-13 | — | — | WO | disclosed |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | ERN1 2855/4885ALDH1A1 4010/4885CYP1A2 2891/4885 |
| US-11723362-B2 | Broad-spectrum synergistic antimicrobial compositions | HAO2, CAT, NACA | ERN1 3391/4885ALDH1A1 669/4885CYP1A2 316/4885 |
| US-11166464-B2 | Self-assembled active agents | PCNA, POLM, MUS81 | ERN1 1744/4885ALDH1A1 110/4885CYP1A2 3390/4885 |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | ERN1 2855/4885ALDH1A1 4010/4885CYP1A2 2891/4885 |
| US-20180303100-A1 | SELF-ASSEMBLED ACTIVE AGENTS | PCNA, POLM, MUS81 | ERN1 1744/4885ALDH1A1 110/4885CYP1A2 3390/4885 |
| US-20210084896-A1 | BROAD-SPECTRUM SYNERGISTIC ANTIMICROBIAL COMPOSITIONS | HAO2, CAT, NACA | ERN1 3391/4885ALDH1A1 669/4885CYP1A2 316/4885 |
| US-20240373854-A1 | SELF-ASSEMBLED ACTIVE AGENTS | PCNA, POLM, MUS81 | ERN1 1744/4885ALDH1A1 110/4885CYP1A2 3390/4885 |
| US-20220015367-A1 | SELF-ASSEMBLED ACTIVE AGENTS | PCNA, POLM, MUS81 | ERN1 1744/4885ALDH1A1 110/4885CYP1A2 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.